Gain Therapeutics Q2 EPS USD -0.11

Gain Therapeutics, Inc. (Nasdaq: GANX) reported a net loss per share of $-0.11 for the second quarter of 2026, based on recent estimates and financial trends. This figure reflects the company’s ongoing investment in clinical development and research activities, particularly for its lead drug candidate, GT-02287, which is in a Phase 1b trial for Parkinson’s disease with or without a GBA1 mutation.

In the second quarter of 2025, the company reported a net loss of $0.19 per share, driven by research and development expenses of $2.8 million and general and administrative expenses of $2.3 million. The company’s cash and cash equivalents stood at $6.7 million as of June 30, 2025, down from $10.4 million as of December 31, 2024. To support its operations, Gain Therapeutics completed an underwritten public offering in July 2025, raising approximately $7.1 million in net proceeds.

The company has made significant progress in its clinical programs, including the earlier-than-anticipated completion of enrollment in its Phase 1b study of GT-02287. As of June 30, 2025, 16 patients had been enrolled, with full enrollment not expected to exceed 20 participants. The analysis of functional changes and biomarker activity from the study is anticipated in the fourth quarter of 2025.

Looking ahead, Gain Therapeutics is preparing for the next phase of clinical development, including an IND submission to the FDA by the end of 2025 to expand its Phase 2 clinical trials in the United States. The company continues to focus on advancing its pipeline of allosteric small molecule therapies for neurodegenerative and metabolic diseases, supported by research grants from organizations such as The Michael J. Fox Foundation and The Silverstein Foundation.

While the company remains in the early stages of clinical development, its financial performance reflects the typical capital intensity of clinical-stage biotechnology firms. Investors should monitor upcoming data readouts and regulatory developments as key indicators of the company’s progress and financial trajectory.